MACM
NBIX icon

March Altus Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

March Altus Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-17,386
Closed -$692K – 12
2015
Q3 		$692K Buy
17,386
+8,793
+102% +$425K 4.08% 12
2015
Q2 		$410K Buy
+8,593
New +$364K 2.38% 17

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

March Altus Capital Management's NBIX Position: Q4 2015 in Review

March Altus Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2015, closing a stake of 17,386 shares — an estimated $692K sold.

March Altus Capital Management first reported a position in NBIX in Q2 2015 and held it in 2 quarters. The position peaked at $692K in Q3 2015. 219 funds tracked by Wall St. Rank hold NBIX as of Q4 2015.

  • March Altus Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2015 after selling out during the quarter.
  • March Altus Capital Management sold 17,386 Neurocrine Biosciences shares in Q4 2015, an estimated $692K.
  • March Altus Capital Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 2 quarters.
  • March Altus Capital Management's Neurocrine Biosciences position peaked at $692K in Q3 2015.
  • 219 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2015.

Based on March Altus Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.